Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes

Diabetes Research and Clinical Practice
Michelle FungG S Meneilly

Abstract

Islet transplantation can improve glycemic control in patients with type 1 diabetes and reduce or eliminate the need for insulin. Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion, and has a trophic effect on beta-cells. We evaluated the effect of GLP-1 on insulin secretion after islet transplantation. Patients underwent hyperglycemic glucose clamp studies 1 month after their last transplant. GLP-1 was infused during the second hour of the hyperglycemic clamp. Results were compared to normal control subjects and patients with type 2 diabetes who underwent an identical hyperglycemic clamp. First phase insulin release was absent in patients, while second phase insulin was not significantly reduced (control: 118+/-29 pM; type 2 diabetes: 68+/-20 pM; transplant: 99+/-18 pM, p=ns for all). GLP-1 had a significant incretin effect on transplanted islets but the response was less than controls (control: 2108+/-344 pM; type 2 diabetes: 929+/-331 pM; transplant: 329+/-112 pM, p<0.0001 control versus transplant). Islet transplant patients had no evidence of resistance to insulin mediated glucose disposal. We conclude that transplanted islets retain the ability to respon...Continue Reading

References

Feb 4, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·L Luzi
Jun 1, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G FillerB Hocher
Feb 13, 2001·Endocrinology·D J Drucker
Mar 29, 2001·Diabetes·J H NielsenC Carlsson
Dec 24, 2004·Diabetes·Michael R RickelsKaren L Teff

❮ Previous
Next ❯

Citations

Aug 9, 2013·Current Diabetes Reports·Yong WangJose Oberholzer
Oct 21, 2011·Journal of Transplantation·Cyrus JahansouzKenneth L Brayman
Dec 8, 2007·Endocrinology·Irene HadjiyanniDaniel J Drucker
Oct 30, 2008·The Journal of Clinical Endocrinology and Metabolism·Michael R RickelsAli Naji
Jun 15, 2007·World Journal of Surgery·Garth L WarnockDavid Thompson
Jan 16, 2007·Transplantation·Khalid Al GhofailiDavid M Thompson
Dec 17, 2009·Annals of Surgery·Dana K Andersen, Charles F Frey
May 24, 2007·The Journal of Clinical Endocrinology and Metabolism·Sven PörksenUNKNOWN Hvidøre Study Group on Childhood Diabetes
Jul 19, 2014·Pancreas·Atsushi MikiHirohito Ichii
Jan 18, 2014·Transplantation·Shireene R VethakkanGlenn M Ward
Apr 29, 2008·Arquivos brasileiros de endocrinologia e metabologia·Mônica de A Lima Gabbay
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.